Decitabine and CHG regimen (low-dose cytarabine and homoharringtonine with G-CSF)
have been used for treating higher risk myelodysplastic syndrome (MDS). In this study, we …

BACKGROUND. Therapy for patients with myelodysplastic syndrome (MDS) with
hypomethylating agents, like decitabine and 5‐azacitidine, has produced favorable results …

BACKGROUND Decitabine, a hypomethylating agent, is active and has been approved for
the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia …

We retrospectively studied 133 myelodysplastic syndrome patients receiving decitabine
during January 2009 and September 2017. The dose of 15 mg/m 2/d (n= 83) and 20 mg/m …

Decitabine has been approved for the treatment of all subtypes of myelodysplastic syndrome
(MDS). However, the optimal regimen for decitabine treatment is not well established. In this …

Nowadays, the regular recommended dose of decitabine for the treatment of
myelodysplastic syndrome (MDS) is 20 mg/m2/day for 5 consecutive days with a relatively …

Purpose This open-label, randomized phase II trial assessed efficacy and tolerability of two
low-dose regimens of subcutaneous (SC) decitabine in patients with low-or intermediate-1 …

The management of myelodysplastic syndrome (MDS) remains challenging. We performed
a phase I/II study to evaluate the safety and efficacy of decitabine in patients with MDS in …

This study was purposed to compare the clinical efficacy and adverse reactions of low-dose
decitabine combined with CAG regimen (aclarubicin, Ara-C, and G-CSF) and CAG regimen …

Decitabine, a hypomethylating agent, has shown activity in MDS, acute myeloid leukemia
(AML), and chronic myeloid leukemia. In this study, we investigated optimizing the dose …